Investors & Media

Investors & Media

Welcome to our investor page

Harnessing the immune system’s full potential to fight human disease.

Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. We exploit a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Our broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on our deep expertise in mRNA vaccine development and in-house manufacturing capabilities, we and our collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside a diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.


Press Releases

25 February 2021

Pfizer and BioNTech Initiate a Study as Part of Broad Development Plan to Evalu..

19 February 2021

Pfizer and BioNTech Submit COVID-19 Vaccine Stability Data at Standard Freezer ..

18 February 2021

Pfizer and BioNTech Commence Global Clinical Trial to Evaluate COVID-19 Vaccine..

Press releases (more)

Upcoming Events

March 1, 2021 from 8:00 AM to 9:00 AM EST

Cowen Healthcare Conference

March 2 - March 4, 2021

2021 Credit Suisse London Global Healthcare Conference

Upcoming events (more)

Stock Quote

Feb 26, 2021 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.